Financial ties between leaders of influential US professional medical associations and industry: cross sectional study
暂无分享,去创建一个
[1] B. Thombs,et al. Pathways to independence: towards producing and using trustworthy evidence , 2019, BMJ.
[2] D. Morgan,et al. 2019 Update on Medical Overuse: A Review. , 2019, JAMA internal medicine.
[3] Fabrice Andre,et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] F. Godlee,et al. Commercial interests, transparency, and independence: a call for submissions , 2019, BMJ.
[5] P. Glasziou,et al. Reforming disease definitions: a new primary care led, people-centred approach , 2019, BMJ Evidence-Based Medicine.
[6] Akihiko Ozaki,et al. Pharmaceutical Company Payments to Executive Board Members of Professional Medical Associations in Japan , 2019, JAMA internal medicine.
[7] J. Halter,et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. , 2019, The Journal of clinical endocrinology and metabolism.
[8] I. Jatoi,et al. Clinical practice guidelines and the overuse of health care services: need for reform , 2019, Canadian Medical Association Journal.
[9] K. Bielefeldt,et al. Assessment of Pharmaceutical Company and Device Manufacturer Payments to Gastroenterologists and Their Participation in Clinical Practice Guideline Panels , 2018, JAMA network open.
[10] John M S Bartlett,et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Detsky,et al. Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study , 2017, British Medical Journal.
[12] R. Moynihan,et al. Mapping the drivers of overdiagnosis to potential solutions , 2017, British Medical Journal.
[13] L. Bero,et al. Industry sponsorship and research outcome. , 2017, The Cochrane database of systematic reviews.
[14] D. Kreiner,et al. Guideline summary review: an evidence-based clinical guideline for the diagnosis and treatment of adult isthmic spondylolisthesis. , 2016, The spine journal : official journal of the North American Spine Society.
[15] Alison B. Evert,et al. Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.
[16] Grace A Lin,et al. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. , 2016, JAMA internal medicine.
[17] Florence T. Bourgeois,et al. Conflict of interest disclosure in biomedical research: a review of current practices, biases, and the role of public registries in improving transparency , 2016, Research Integrity and Peer Review.
[18] Charles H. Cho,et al. Guideline summary review: An evidence-based clinical guideline for the diagnosis and treatment of degenerative lumbar spondylolisthesis. , 2016, The spine journal : official journal of the North American Spine Society.
[19] D. Rothman. Professional Medical Associations and Divestiture from Industry: An Ethical Imperative for Pain Society Leadership. , 2016, Pain medicine.
[20] E. Bleecker,et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.
[21] L. Jovanovič,et al. Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline , 2013, The Journal of clinical endocrinology and metabolism.
[22] S. Hill,et al. Expanding Disease Definitions in Guidelines and Expert Panel Ties to Industry: A Cross-sectional Study of Common Conditions in the United States , 2013, PLoS medicine.
[23] D. Berwick,et al. Eliminating waste in US health care. , 2012, JAMA.
[24] Amy T. Wang,et al. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review , 2010, BMJ : British Medical Journal.
[25] A. Evensen. Management of COPD exacerbations. , 2010, American family physician.
[26] Marilyn J. Field,et al. Conflict of Interest in Medical Research, Education, and Practice , 2009 .
[27] R. L. Addleton,et al. Industry support and professional medical associations. , 2009, JAMA.
[28] M. Talamini,et al. Industry support and professional medical associations. , 2009, JAMA.
[29] C. Deangelis,et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. , 2009, JAMA.
[30] K. Garey,et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] J. Lexchin,et al. Continuing medical education and pharmaceutical industry involvement: An evaluation of policies adopted by Canadian professional medical associations. , 2017, The International journal of risk & safety in medicine.
[32] Agnès Couffinhal,et al. Tackling Wasteful Spending on Health , 2017 .
[33] S. Temin,et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2016, Journal of oncology practice / American Society of Clinical Oncology.
[34] Wu Guo-cheng,et al. Prevention of COPD Exacerbations , 2012 .
[35] Declaration of Interests for WHO experts. , 2002, International journal of occupational and environmental health.